PubRank

Xiumin Wu

Author PubWeight™ 49.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007 6.76
2 Therapeutic antibody targeting of individual Notch receptors. Nature 2010 4.56
3 PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009 3.71
4 Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007 3.70
5 Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2005 3.30
6 An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 2013 3.00
7 Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A 2010 2.77
8 G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 2009 2.68
9 Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 2012 2.21
10 PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010 1.75
11 Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 2007 1.73
12 Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008 1.63
13 Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009 1.56
14 Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 2008 1.51
15 Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 2006 1.29
16 Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A 2011 1.26
17 Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A 2013 1.25
18 Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol 2012 1.11
19 A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 2010 1.10
20 Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res 2013 1.02
21 Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res 2008 0.97
22 Quantification of viable tumor microvascular characteristics by multispectral analysis. Magn Reson Med 2008 0.90
23 Mesenchymal stem cells promote epithelial to mesenchymal transition and metastasis in gastric cancer though paracrine cues and close physical contact. J Cell Biochem 2015 0.82
24 Long-term physical exercise and atrial natriuretic peptide in obese Zucker rats. Pharmacol Toxicol 2002 0.75